AstraZeneca reports positive liver cancer study results for Imfinzi

seekingalpha01-20

AstraZeneca (NASDAQ:AZN) said that a Phase 3 trial for its drug Imfinzi plus transarterial chemoembolization, or TACE, and bevacizumab showed the combination significantly reduced the risk of death in...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2404663776?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-01-20 05:55","share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","id":"2404663776","market":"us","top_or_hot":-1,"title":"AstraZeneca reports positive liver cancer study results for Imfinzi","media":"seekingalpha","content":"<div>\n<p>AstraZeneca (NASDAQ:AZN) said that a Phase 3 trial for its drug Imfinzi plus transarterial chemoembolization, or TACE, and bevacizumab showed the combination significantly reduced the risk of death in...</p>\n\n<a href=\"https://seekingalpha.com/news/4056613-astrazeneca-reports-positive-liver-cancer-study-results-for-imfinzi\">Source Link</a>\n\n</div>\n","source":"seekingalpha","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AstraZeneca reports positive liver cancer study results for Imfinzi</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAstraZeneca reports positive liver cancer study results for Imfinzi\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-01-20 05:55 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/4056613-astrazeneca-reports-positive-liver-cancer-study-results-for-imfinzi><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>AstraZeneca (NASDAQ:AZN) said that a Phase 3 trial for its drug Imfinzi plus transarterial chemoembolization, or TACE, and bevacizumab showed the combination significantly reduced the risk of death in...</p>\n\n<a href=\"https://seekingalpha.com/news/4056613-astrazeneca-reports-positive-liver-cancer-study-results-for-imfinzi\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0889565916.HKD","symbol_name":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","start_time":0,"source_url":"https://seekingalpha.com/news/4056613-astrazeneca-reports-positive-liver-cancer-study-results-for-imfinzi","article_id":"2404663776","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2404663776","pubTimestamp":1705701340,"sourceInfo":{"source_id":"seekingalpha","name":"Seeking Alpha"},"weMediaInfo":null,"summary":"AstraZeneca  said that a Phase 3 trial for its drug Imfinzi plus transarterial chemoembolization, or TACE, and bevacizumab showed the combination significantly reduced the risk of death in certain liver cancer patients.  The drugmaker said that Imfinzi, also known as durvalumab, in combination with TACE and bevacizumab was able to lower the risk of death or disease progression by 23% versus TACE in treating patients with hepatocellular carcinoma, or HCC, eligible for embolization.  The study’s primary endpoint was progression-free survival. Bevacizumab is also known as Avastin.  AstraZeneca said that about 20% to 30% of patients with HCC are eligible for embolization. HCC is the most common type of liver cancer. The study results were presented Friday at the 2024 American Society of Clinical Oncology Gastrointestinal Cancers Symposium in San Francisco.   More on AstraZeneca  Why AstraZeneca's Gracell Biotechnologies Acquisition Is A Win-Win AstraZeneca: A $1.1B Shot In The Arm From Ico","collect":0,"end_time":0,"defaultTopTitle":"seekingalpha.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","LU1829250122.USD":"高盛欧洲核心股票组合Acc","LU2236285917.USD":"ALLIANZ GLOBAL INCOME \"AMG\" (USD) INC","BK4585":"ETF&股票定投概念","BK4139":"生物科技","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","BK4539":"次新股","ICVX":"Icosavax, Inc.","BK4568":"美国抗疫概念","BK4007":"制药","AZN":"阿斯利康","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)"},"translate_title":"阿斯利康报告Imfinzi肝癌研究结果呈阳性","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AZN":1,"ICVX":0.64},"content_text":"AstraZeneca (NASDAQ:AZN) said that a Phase 3 trial for its drug Imfinzi plus transarterial chemoembolization, or TACE, and bevacizumab showed the combination significantly reduced the risk of death in certain liver cancer patients.  The drugmaker said that Imfinzi, also known as durvalumab, in combination with TACE and bevacizumab was able to lower the risk of death or disease progression by 23% versus TACE in treating patients with hepatocellular carcinoma, or HCC, eligible for embolization.  The study’s primary endpoint was progression-free survival. Bevacizumab is also known as Avastin.  AstraZeneca said that about 20% to 30% of patients with HCC are eligible for embolization. HCC is the most common type of liver cancer. The study results were presented Friday at the 2024 American Society of Clinical Oncology Gastrointestinal Cancers Symposium in San Francisco.   More on AstraZeneca  Why AstraZeneca's Gracell Biotechnologies Acquisition Is A Win-Win AstraZeneca: A $1.1B Shot In The Arm From Icosavax Acquisition AstraZeneca Is Feeling The Weight Of The Market In 2023 AstraZeneca PNH drug gets first regulatory approval in Japan Icosavax ticks lower as HSR filing for AstraZeneca deal withdrawn, refiled","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2404663776"}